quinoxalines has been researched along with Carcinoma, Transitional Cell in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 21 (80.77) | 2.80 |
| Authors | Studies |
|---|---|
| Claiborne, RT; Tsan, GL | 1 |
| Avadhani, A; De Porre, P; Dosne, AG; Goeyvaerts, N; Li, LY; O'Hagan, A; Ouellet, D; Perez Ruixo, JJ; Valade, E | 1 |
| Akapame, S; Burgess, EF; Duran, I; Fleming, MT; García-Donas, J; Huddart, RA; Joshi, M; Loriot, Y; Mellado, B; Monga, M; Necchi, A; O'Hagan, A; Park, SH; Rezazadeh Kalebasty, A; Santiago-Walker, AE; Siefker-Radtke, AO; Tagawa, ST; Varlamov, S; Zakharia, Y | 1 |
| Loriot, Y; Siefker-Radtke, AO | 1 |
| Cosmai, L; Franza, A; Giannatempo, P; Pirovano, M | 1 |
| Belal, F; El-Enany, N; Elawady, T; Khedr, A | 1 |
| Arai, S; Fujizuka, Y; Kato, M; Koike, H; Maeno, Y; Matsui, H; Miyazawa, Y; Ohtsu, A; Sawada, T; Sekine, Y; Suzuki, K | 1 |
| Chang, SS | 1 |
| Bellmunt, J; Montazeri, K | 1 |
| Kolesar, JM; Myint, ZW; Roubal, K | 1 |
| Grülllich, C | 1 |
| Burgess, M; English, A; Hartmann, A; Major, C; Sweeney, M; Wang, S | 1 |
| Galsky, MD; Patel, V; Qin, Q | 1 |
| Amir, M; Javed, S; Qureshi, MA | 1 |
| Ertl, IE; Ilijazi, D; Loriot, Y; Mostafaei, H; Shariat, SF | 1 |
| Bagby, S; Bortoletti, C; D'Angelo, A; Galli, IC; Roviello, G | 1 |
| Montazeri, K; Sonpavde, G | 1 |
| Bossaer, JB; Weaver, A | 1 |
| Bansal, P; Dwivedi, DK; Goyal, S; Gupta, V; Hatwal, D; Maithani, M; Sharma, P | 1 |
| Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A | 1 |
| Kim, HS; Seo, HK | 1 |
| Markham, A | 1 |
| He, S; Li, X; Martin, DT; Tian, Y; Weiss, RM | 1 |
| Burki, TK | 1 |
| Bastaros, JM; Carles, J; de Castro, AM; Maldonado, X; Morales-Barrera, R; Morote, J; Racca, F; Suárez, C; Valverde, C | 1 |
| Archer, CL; Haas, GP; Jones, RF; Morse, P; Shirai, T; Wang, CY | 1 |
12 review(s) available for quinoxalines and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2022 |
Erdafitinib for the treatment of metastatic bladder cancer.
Topics: Animals; Carcinoma, Transitional Cell; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2020 |
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2020 |
[High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Treatment Outcome; Urologic Neoplasms; Urothelium | 2020 |
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Development; Humans; Immune Checkpoint Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Urinary Bladder Neoplasms | 2020 |
Fibroblast growth factor receptors across urothelial carcinoma landscape.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2020 |
Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Disease Progression; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2020 |
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Topics: Bile Duct Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3 | 2021 |
Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2021 |
Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Genes, Viral; Genetic Therapy; Humans; Hyperthermia; Immune Checkpoint Inhibitors; Immunoconjugates; Organ Sparing Treatments; Photochemotherapy; Pyrazoles; Quinoxalines; Retreatment; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Ipilimumab; Nivolumab; Phenylurea Compounds; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2016 |
3 trial(s) available for quinoxalines and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Survival Rate; Urinary Bladder Neoplasms | 2022 |
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Topics: Aged; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; ErbB Receptors; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2022 |
Erdafitinib for advanced urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms; Urothelium | 2019 |
11 other study(ies) available for quinoxalines and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
Topics: Aged, 80 and over; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; Female; Humans; Male; Protein Kinase Inhibitors; Pyrazoles; Quality of Life; Quinoxalines; Receptors, Fibroblast Growth Factor; United States; Urinary Bladder Neoplasms | 2022 |
Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2022 |
Utility of Kolliphor RH 40 in micellar sensitized fluorescence of the novel tyrosine kinase inhibitor "Erdafitinib": Application to human plasma.
Topics: Carcinoma, Transitional Cell; Humans; Micelles; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Solvents; Spectrometry, Fluorescence; Urinary Bladder Neoplasms | 2022 |
Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Carcinoma, Transitional Cell; Cell Line, Tumor; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor | 2022 |
Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Pyrazoles; Quinoxalines; Urologic Neoplasms | 2020 |
Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Pyrazoles; Quinoxalines; Real-Time Polymerase Chain Reaction; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms | 2020 |
Biomolecular interactions and binding dynamics of tyrosine kinase inhibitor erdafitinib, with human serum albumin.
Topics: Binding Sites; Carcinoma, Transitional Cell; Circular Dichroism; Humans; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics; Tumor Microenvironment; Urinary Bladder Neoplasms | 2021 |
FGFR alterations in urothelial carcinoma: Picking the right target.
Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms | 2021 |
Erdafitinib: First Global Approval.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Approval; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Treatment Outcome; United States; United States Food and Drug Administration; Urologic Neoplasms | 2019 |
Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth.
Topics: Butadienes; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydrazines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Nitriles; Quinoxalines; Urinary Bladder Neoplasms | 2019 |
Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 2-amino-3, 8-dimethyl-imidazo[4,5-f]quinoxaline and 3, 2'-dimethyl-4-aminobiphenyl in the rat.
Topics: Aminobiphenyl Compounds; Animals; Animals, Newborn; Body Weight; Carcinogens; Carcinoma, Transitional Cell; Colonic Neoplasms; Hyperplasia; Imidazoles; Male; Mutagens; Prostatic Neoplasms; Pyridines; Quinoxalines; Rats; Rats, Inbred ACI; Urinary Bladder Neoplasms | 2000 |